Hatch/Waxman Incentives Could Make BTC A Win – Consultant
This article was originally published in The Pink Sheet Daily
Executive Summary
Hatch/Waxman exclusivity for up to five years can provide incentive for drug firms to go behind the counter with Rx products, consultant says at FDA’s BTC meeting.